{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:59:09Z","timestamp":1780822749852,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024789","name":"Fundaci\u00f3n de la Comunidad Valenciana Centro de Investigaci\u00f3n Pr\u00edncipe Felipe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neuropharm.2025.110759","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:49:02Z","timestamp":1762328942000},"page":"110759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathway"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-8513","authenticated-orcid":false,"given":"Maria A.","family":"Pedrosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-7060","authenticated-orcid":false,"given":"Gergana","family":"Mincheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Martinez-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-0724","authenticated-orcid":false,"given":"Magnus","family":"Doverskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-5907","authenticated-orcid":false,"given":"Marta","family":"Llansola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3145-9538","authenticated-orcid":false,"given":"Vicente","family":"Felipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110759_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18368","article-title":"BDNF\/trkB activators in Parkinson's disease: a new therapeutic strategy","volume":"28","author":"Ali","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110759_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112575","article-title":"DRD1 signaling modulates TrkB turnover and BDNF sensitivity in direct pathway striatal medium spiny neurons","volume":"42","author":"Andreska","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2025.110759_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12799","article-title":"The S1PR2-CCL2-BDNF-TrkB pathway mediates neuroinflammation and motor incoordination in hyperammonaemia","volume":"48","author":"Arenas","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110759_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/liv.15782","article-title":"Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation","volume":"44","author":"Arenas","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.neuropharm.2025.110759_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12974-024-03310-5","article-title":"A transient blood IL-17 increase triggers neuroinflammation in cerebellum and motor incoordination in hyperammonemic rats","volume":"21","author":"Arenas","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110759_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110759_bib7","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/acschemneuro.5b00212","article-title":"Roles of NMDA receptor and EAAC1 transporter in modulation of extracellular glutamate by low and high affinity AMPA receptors in cerebellum in vivo. Differential alteration in chronic hyperammonemia","volume":"16","author":"Cabrera-Pastor","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110759_bib8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbi.2017.12.013","article-title":"Increasing extracellular cGMP in cerebellum in vivo reduces neuroinflammation, GABAergic tone and motor in-coordination in hyperammonemic rats","volume":"69","author":"Cabrera-Pastor","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2025.110759_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1326-8-14","article-title":"Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits","volume":"8","author":"Carvalho","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110759_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbi.2020.11.038","article-title":"Glutaminase in microglia: a novel regulator of neuroinflammation","volume":"92","author":"Ding","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2025.110759_bib11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2025.110759_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fnana.2017.00109","article-title":"Application of the physical disector principle for quantification of dopaminergic neuronal loss in a rat 6-Hydroxydopamine nigral lesion model of Parkinson's disease","volume":"11","author":"Fabricius","year":"2017","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2025.110759_bib13","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1471-4159.1993.tb13384.x","article-title":"Ammonium injection induces an N-methyl-D-aspartate receptor-mediated proteolysis of the microtubule-associated protein MAP-2","volume":"60","author":"Felipo","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110759_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.682460","article-title":"A computational study of astrocytic GABA release at the glutamatergic synapse: EAAT-2 and GAT-3 coupled dynamics","volume":"15","author":"Flanagan","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110759_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007153","article-title":"Glutamate uptake triggers transporter-mediated GABA release from astrocytes","volume":"4","author":"H\u00e9ja","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110759_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1741-7007-10-26","article-title":"Astrocytes convert network excitation to tonic inhibition of neurons","volume":"10","author":"H\u00e9ja","year":"2012","journal-title":"BMC Biol."},{"key":"10.1016\/j.neuropharm.2025.110759_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.05.006","article-title":"Feedback adaptation of synaptic excitability via Glu:Na+ symport driven astrocytic GABA and Gln release","volume":"161","author":"H\u00e9ja","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110759_bib18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cub.2019.11.079","article-title":"Aberrant tonic inhibition of dopaminergic neuronal activity causes motor symptoms in animal models of Parkinson's Disease","volume":"30","author":"Heo","year":"2020","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110759_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12974-016-0549-z","article-title":"Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia","volume":"13","author":"Hernandez-Rabaza","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110759_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2005.02.023","article-title":"Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice","volume":"162","author":"Iancu","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110759_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1417938","article-title":"Golexanolone reduces glial activation in the striatum and improves non-motor and some motor alterations in a rat model of Parkinson's disease","volume":"16","author":"Izquierdo-Altarejos","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110759_bib22","doi-asserted-by":"crossref","first-page":"G400","DOI":"10.1152\/ajpgi.00073.2015","article-title":"GR3027 antagonizes GABAA receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy","volume":"309","author":"Johansson","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.neuropharm.2025.110759_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jsbmb.2015.10.019","article-title":"GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo","volume":"160","author":"Johansson","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2025.110759_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105028","article-title":"Microglia and astrocyte dysfunction in Parkinson'S disease","volume":"144","author":"Kam","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"24","key":"10.1016\/j.neuropharm.2025.110759_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415859","article-title":"GABA release from astrocytes in health and disease","volume":"23","author":"Kilb","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110759_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mdc3.12343","article-title":"The pathophysiology of fatigue in Parkinson's disease and its pragmatic management","volume":"3","author":"Kosti\u0107","year":"2016","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2025.110759_bib27","first-page":"580","article-title":"Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy","volume":"9","author":"Kuipers","year":"2006","journal-title":"Curr. Opin. Drug Discov. Dev"},{"key":"10.1016\/j.neuropharm.2025.110759_bib28","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.neuron.2016.04.040","article-title":"Enhanced GABA transmission drives Bradykinesia following loss of dopamine D2 receptor signaling","volume":"90","author":"Lemos","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2025.110759_bib29","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1460-9568.2012.08162.x","article-title":"Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?","volume":"35","author":"Lindgren","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110759_bib30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2025.110759_bib31","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/cns.13926","article-title":"Golexanolone, a GABAA receptor modulating steroid antagonist, restores motor coordination and cognitive function in hyperammonemic rats by dual effects on peripheral inflammation and neuroinflammation","volume":"28","author":"Mincheva","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2025.110759_bib32","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/ijms21020590","article-title":"TGF-\u03b2\/Smad3 signalling modulates GABA neurotransmission: implications in Parkinson's disease","volume":"21","author":"Mu\u00f1oz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110759_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/0118715249268627231206115942","article-title":"Glutamate receptors and C-ABL inhibitors: a new therapeutic approach for Parkinson's disease","volume":"24","author":"Shejul","year":"2024","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110759_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612664","article-title":"Neuronal death caused by HMGB1-Evoked via inflammasomes from thrombin-activated microglia cells","volume":"24","author":"Sheu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110759_bib35","doi-asserted-by":"crossref","first-page":"21362","DOI":"10.1074\/jbc.M600504200","article-title":"Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner","volume":"281","author":"Takeuchi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110759_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2792348","article-title":"Hydrogen sulfide attenuates the cognitive dysfunction in Parkinson's disease rats via promoting hippocampal microglia M2 polarization by enhancement of hippocampal warburg effect","author":"Tian","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuropharm.2025.110759_bib37","article-title":"6-OHDA lesion models of parkinson's disease in the rat","volume":"vol. 61","author":"Torres","year":"2011"},{"key":"10.1016\/j.neuropharm.2025.110759_bib38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00702-018-1900-6","article-title":"Levodopa-induced dyskinesia: clinical features, incidence, and risk factors","volume":"125","author":"Tran","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.neuropharm.2025.110759_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.585584","article-title":"Molecular mechanisms of glutamate toxicity in Parkinson's disease","volume":"14","author":"Wang","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110759_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1308345","article-title":"New insight on microglia activation in neurodegenerative diseases and therapeutics","volume":"17","author":"Xu","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110759_bib41","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2147\/NDT.S403002","article-title":"Parkinson's disease related depression and anxiety: a 22-Year bibliometric analysis (2000-2022)","volume":"19","author":"Zhang","year":"2023","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2025.110759_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00018-022-04574-x","article-title":"The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis","volume":"79","author":"Zhou","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110759_bib43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7","article-title":"Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion","volume":"427","author":"Zuch","year":"2000","journal-title":"J. Comp. Neurol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:21:12Z","timestamp":1780820472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":43,"alternative-id":["S0028390825004678"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110759","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathway","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110759"}}